Evidence map›Paper›PMID 40726286›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Tetrahydropyranyl Backbone Protection for Enhanced Fmoc Solid-Phase Peptide Synthesis.

Samuel J Paravizzini, Craig A Hutton, John A Karas

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Backbone Protecting Groups for Enhanced Peptide and Protein Synthesis.Angewandte Chemie (International ed. in English) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samuel J ParavizziniSchool of Chemistry, The University of Melbourne, Parkville, VIC, 3010, Australia.
Craig A HuttonSchool of Chemistry, The University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-2353-9258
John A KarasSchool of Chemistry, The University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-3800-5152

Funding

Australian Research CouncilDiscovery Early Career Researcher Award DE220101329
6 · The paper itself

Abstract

Fmoc solid-phase peptide synthesis has been indispensable for the efficient manufacture of research grade peptides and proteins, and peptide APIs. However, the solid-phase approach is still hampered by solubility issues and aggregation of the resin-bound peptide chain, which limits routine access to peptides > 40 amino acids in length. The use of backbone amide protecting groups, such as through the introduction of N-benzyl-based moieties and pseudoproline dipeptides, ameliorates this synthetic inefficiency somewhat. But benzyl groups can be difficult to remove postassembly, and pseudoprolines are limited to serine, threonine, and cysteine-rich peptide segments. To enhance the utility of backbone protection, we have evaluated the tetrahydropyranyl (Thp) group as a more acid labile alternative to benzyl protection. The Thp group can be efficiently introduced to the resin-bound peptide as a protected dipeptide and is readily cleaved and scavenged postsynthesis. A drastic improvement in the solid-phase assembly of aggregation-prone amyloid-β and prion-derived peptide fragments is observed using Thp as a backbone protecting group. We envisage that Thp-protected dipeptides will become useful building blocks for peptide manufacturing, complementing existing backbone protecting group strategies.

Indexed as

FluorenesPeptidesSolid-Phase Synthesis TechniquesAmino AcidsAmyloid beta-PeptidesDipeptidesAmino AcidsAmyloid beta-PeptidesDipeptidesFluorenesN(alpha)-fluorenylmethyloxycarbonylamino acidsPeptidesamideamino acidprotecting groupsolid‐phase peptide synthesistetrahydropyranyl

Identifiers

PMID40726286
PMCPMC12351424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.